Literature DB >> 8625110

Additional experience with empiric radiotherapy for presumed human immunodeficiency virus-associated primary central nervous system lymphoma.

B R Donahue1, J W Sullivan, J S Cooper.   

Abstract

BACKGROUND: In light of the steadily improving capability to treat opportunistic infections, the authors reviewed their recent experience with short course empiric radiotherapy for the treatment of human immunodeficiency virus (HIV)-associated presumed central nervous system (CNS) lymphoma.
METHODS: Medical records were reviewed of 32 previously unreported HIV-infected patients who had computed tomography and/or magnetic resonance imaging findings consistent with lymphoma, whose lesions had failed to respond to antitoxoplasmosis therapy and therefore subsequently treated with empiric radiotherapy to the cranium and meninges, nearly always 3000 cGy in 10 fractions.
RESULTS: The majority of patients were in poor general condition (median Karnofsky score = 50) when radiotherapy was initiated. Fifty percent improved during or after radiation. Median survival was 2.1 months.
CONCLUSIONS: Despite progress made in the past several years in the treatment of opportunistic infections and brief clinical response to radiotherapy, patients with acquired immunodeficiency syndrome who have a presumed diagnosis of CNS lymphoma continue to have extremely poor survival. Early biopsy in patients with lesions that fail to respond to empiric antitoxoplasmosis treatment or with lesions radiographically most consistent with lymphoma may improve outcome.

Entities:  

Mesh:

Year:  1995        PMID: 8625110     DOI: 10.1002/1097-0142(19950715)76:2<328::aid-cncr2820760225>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate.

Authors:  Kathryn Lurain; Thomas S Uldrick; Ramya Ramaswami; Mark N Polizzotto; Priscila H Goncalves; Anaida Widell; Seth M Steinberg; Elaine S Jaffe; Stefania Pittaluga; Hao-Wei Wang; Constance M Yuan; Mary Anne Tamula; Staci Martin; Pamela L Wolters; Jomy George; Richard F Little; Robert Yarchoan
Journal:  Blood       Date:  2020-11-05       Impact factor: 22.113

2.  AIDS-related central nervous system lymphomas.

Authors:  M C Chamberlain; P A Kormanik
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

Review 3.  Management of AIDS-related non-Hodgkin's lymphomas.

Authors:  M J Kersten; R H Van Oers
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  An unusual and challenging case of HIV-associated primary CNS Lymphoma with Hodgkin-like morphology and HIV encephalitis.

Authors:  Isaac E Lloyd; Parker W Clement; Karen L Salzman; Randy L Jensen; Mohamed E Salama; Cheryl A Palmer
Journal:  Diagn Pathol       Date:  2015-09-02       Impact factor: 2.644

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.